Shares of Nuformix plc (LON:NFX – Get Free Report) were down 9.7% during trading on Monday . The stock traded as low as GBX 0.14 ($0.00) and last traded at GBX 0.14 ($0.00). Approximately 2,727,746 shares were traded during trading, a decline of 15% from the average daily volume of 3,191,435 shares. The stock had previously closed at GBX 0.16 ($0.00).
Nuformix Stock Performance
The stock has a 50 day moving average price of GBX 0.17 and a two-hundred day moving average price of GBX 0.19. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.12 and a quick ratio of 3.35. The company has a market capitalization of £1.31 million, a price-to-earnings ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- NYSE Stocks Give Investors a Variety of Quality Options
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- How to Read Stock Charts for Beginners
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
